Medicus AI Closes the First Tranche of its Series A Funding Round of €5 Million

MedicusMedicus AI GmbH announced the completion of the first tranche of its Series A funding round at €2.75 million, with the purview to close the second tranche of €2.25 million over the coming months.

Medicus works with diagnostic labs to deliver smart features and insights to doctors, in terms of smart testing and diagnosis support, and to patients, in the form of visual and interactive reports, powering continuous healthcare and coaching across all digital platforms.

"At Medicus, we believe that healthcare is in dire need of a user-experience overhaul and that people today are used to experiencing things in a much simpler and clearer fashion, yet healthcare is still complex and impenetrable. We believe this augmentation can unlock massive value that reverberates across the whole healthcare system," said Dr Baher al Hakim, CEO, Medicus.

The Series A funding round will further fuel the company's global expansion, as well as the development of the Medicus diagnostic lab and insurance products, across core markets and in new languages. To date, Medicus supports, German, French, English and Arabic, with Italian, Chinese, Portuguese and Spanish in the pipeline for 2019.

The diagnostic lab space, which makes up Medicus' current core client base, generates an estimated 20 billion reports annually worldwide. However, the industry operates in highly consolidated markets and struggle to differentiate themselves, maintain growthand introduce future-proof business models.

"Our proposition to diagnostic labs is simple. We empower labs to deliver defensible value-add services that augment their existing products. We believe that lab directors only have a few years to decide how to react to the impending waves of innovation incrementally disrupting their industry. The market is struggling under increased commoditization, lowering margins and tightening regulations. Through innovation we help labs build an attractive and integral service offering," explained Dr Baher.

Today Medicus is focused on scalable distribution strategies in existing and new markets from its Vienna headquarters, with offices in Berlin, Paris and Beirut. In late 2018, Medicus signed a market access cooperation with Roche Diagnostics, which will amplify its global reach.

"Medicus is working towards transforming the healthcare sector, simplifying the relations between providers and patients, and leading to better health outcomes," concluded Dr Baher. "Our growing global knowledge and partnerships will help us achieve these outcomes."

For further information, please visit:
http://www.medicus.ai

About Medicus

Medicus is an AI-based platform that converts health data into an interactive experience with easy-to-understand explanations, personalized health insights and smart wellbeing coaching.

Medicus is used by diagnostic labs and health insurance companies to provide patient-friendly health reports and foster continuous and personalized wellbeing coaching.

Medicus is based in Vienna, with offices in Berlin, Paris and Beirut.

Most Popular Now

AI Distinguishes Glioblastoma from Look-…

A Harvard Medical School–led research team has developed an AI tool that can reliably tell apart two look-alike cancers found in the brain but with different origins, behaviors, and treatments. The...

AI Body Composition Measurements can Pre…

Adiposity - or the accumulation of excess fat in the body - is a known driver of cardiometabolic diseases such as heart disease, stroke, type 2 diabetes, and kidney disease...

AI can Strengthen Pandemic Preparedness

How to identify the next dangerous virus before it spreads among people is the central question in a new Comment in The Lancet Infectious Diseases. In it, researchers discuss how...

'Future-Guided' AI Improves Se…

In the world around us, many things exist in the context of time: a bird’s path through the sky is understood as different positions over a period of time, and...

New AI Tool Scans Social Media for Hidde…

A new artificial intelligence tool can scan social media data to discover adverse events associated with consumer health products, according to a study published September 30th in the open-access journal...